Latest from Dana Farber

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses avelumab/axitinib data in renal cell carcinoma.
Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of Medicine, Harvard Medical School, discusses ongoing trials in soft tissue sarcoma (STS).
Geoffrey R. Oxnard, MD, discusses the use of cell-free DNA as a potential method of cancer detection and subsequent assessment of treatment response in patients with solid and hematologic malignancies.
Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.
Huma Q. Rana, MD, discusses the evolution of genetic testing in ovarian cancer and the genes that are associated with an increased risk of subsequent cancer development.
Susana Campos, MD, MPH, highlights the success with PARP inhibitors in the relapsed and maintenance ovarian cancer settings.
Stephanie K. Dougan, PhD, discusses research aimed at assessing ways of augmenting T-cell immunity in pancreatic cancer.
Dana-Farber Cancer Institute researchers are Grand Challenge winners for a project that aims to discover how certain microbes inside the body lead to colorectal cancer and influence a patient’s response to treatment.
Publication Bottom Border
Border Publication